$Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML$

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML

Xiaotong Chen, Yanqiu Zhao, Qi Li, Shengjin Fan Department of Hematology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, People’s Republic of ChinaCorrespondence: Shengjin Fan, Tel +86-13304641978, Email fansjhmu@163.comPurpose: The prognosis of patients with unfit or re...

Full description

Bibliographic Details
Main Authors:	Chen X, Zhao Y, Li Q, Fan S
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-06-01
Series:	OncoTargets and Therapy
Subjects:	acute myeloid leukemia bcl2 inhibitor venetoclax combined chemotherapy
Online Access:	https://www.dovepress.com/single-center-retrospective-clinical-evaluation-of-venetoclax-combined-peer-reviewed-fulltext-article-OTT

Similar Items

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
by: Yifan Liu, et al.
Published: (2023-11-01)

Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
by: CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia
Published: (2022-03-01)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
by: Hua Jin, et al.
Published: (2023-04-01)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
by: Jorge Labrador, et al.
Published: (2022-03-01)

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
by: Sylvain Garciaz, et al.
Published: (2022-04-01)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
by: Xi Xu, et al.
Published: (2023-10-01)

Venetoclax: A Game Changer in the Treatment of Younger AML Patients?
by: Matteo Molica, et al.
Published: (2023-12-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
by: Xubo Gong, et al.
Published: (2024-02-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
by: Xubo Gong, et al.
Published: (2023-06-01)

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
by: Ramy Rahmé, et al.
Published: (2024-01-01)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
by: Matteo Piccini, et al.
Published: (2023-05-01)

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience
by: Adriana Trabal, et al.
Published: (2023-03-01)

Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience
by: İbrahim Ethem Pınar, et al.
Published: (2021-03-01)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
by: Serena Brancati, et al.
Published: (2021-12-01)

Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
by: Federica Lessi, et al.
Published: (2021-08-01)

Venetoclax Resistance in Acute Myeloid Leukemia
by: Sylvain Garciaz, et al.
Published: (2024-03-01)

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
by: Shlomzion Aumann, et al.
Published: (2022-09-01)

Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia
by: Tzu-Ting Chen, et al.
Published: (2024-03-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience
by: Alicia Roldán Pérez, et al.
Published: (2022-07-01)

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
by: Francesco Angotzi, et al.
Published: (2024-04-01)

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
by: Xuezhu Xu, et al.
Published: (2023-12-01)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
by: Su-Yeon Bang, et al.
Published: (2023-03-01)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

Venetoclax in adult acute myeloid leukemia
by: Mengci Hu, et al.
Published: (2023-12-01)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
by: Matteo Piccini, et al.
Published: (2021-04-01)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
by: Zhangjie Chen, et al.
Published: (2023-03-01)

Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia
by: Joel Brothers, et al.
Published: (2023-12-01)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
by: Emmanuella Oyogoa, et al.
Published: (2023-07-01)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)

Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients
by: Elena Chatzikalil, et al.
Published: (2024-04-01)

Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies
by: Maria Leśniak, et al.
Published: (2023-11-01)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
by: Anna Ferrari, et al.
Published: (2023-05-01)

Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis
by: Jingkui Zhu, et al.
Published: (2024-03-01)

Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia
by: XIANG Caixia, HUANG Bintao, HAO Jian
Published: (2023-05-01)

Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report
by: Yuina Akagi, et al.
Published: (2023-08-01)

A case report of atypical chronic myeloid leukemia with complete hematological and major molecular response to Venetoclax/Azacitidine treatment
by: Hongxia Chen, et al.
Published: (2024-03-01)

Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism
by: Dinh Hoa Hoang, et al.
Published: (2022-03-01)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
by: Mariarita Sciumè, et al.
Published: (2023-03-01)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
by: Mila S. Griffioen, et al.
Published: (2022-07-01)